Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study

Abstract Background The effects of a 21-day combined oral contraceptive containing 30 mcg ethinyl estradiol plus 3 mg drospirenone with a 21-day preparation containing 20 mcg ethinyl estradiol plus 3 mg drospirenone on bone turnover and bone mineral density (BMD) in young fertile women were compared...

Full description

Saved in:
Bibliographic Details
Published in:Contraception (Stoneham) 2008-07, Vol.78 (1), p.10-15
Main Authors: Gargano, Virginia, Massaro, Mariangela, Morra, Ilaria, Formisano, Carmen, Di Carlo, Costantino, Nappi, Carmine
Format: Article
Language:English
Subjects:
Adult
Amino Acids - urine
Androstenes - pharmacology
Biological and medical sciences
Birth control
Bone and Bones - drug effects
Bone and Bones - metabolism
Bone Density - drug effects
Bone mineral density
Bone Remodeling - drug effects
Calcium - blood
Calcium - urine
Combined oral contraceptives
Contraceptives, Oral, Combined
Contraceptives, Oral, Synthetic - pharmacology
Deoxypyridinoline
Dose-Response Relationship, Drug
Ethinyl Estradiol - pharmacology
Female
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Hormonal contraception
Humans
Medical sciences
Obstetrics and Gynecology
Osteocalcin
Osteocalcin - metabolism
Pharmacology. Drug treatments
Pyridinoline
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The effects of a 21-day combined oral contraceptive containing 30 mcg ethinyl estradiol plus 3 mg drospirenone with a 21-day preparation containing 20 mcg ethinyl estradiol plus 3 mg drospirenone on bone turnover and bone mineral density (BMD) in young fertile women were compared. Methods A randomized, controlled trial was conducted on healthy fertile women treated with 30 mcg ethinyl estradiol plus 3 mg drospirenone (Group A; n =21), 20 mcg ethinyl estradiol plus 3 mg drospirenone (Group B; n =23) and healthy controls (Group C; n =21). At 3, 6, 9 and 12 months, serum and urinary calcium, osteocalcin (BGP), urinary pyridinoline and deoxypyridinoline were measured. At baseline and after 12 months, lumbar bone mineral density was determined by dual-energy X-ray absorptiometry. Results In Groups A and B, urinary pyridinoline and deoxypyridinoline at 6, 9 and 12 months were significantly reduced in comparison with basal values and Group C (p
ISSN:0010-7824
1879-0518
DOI:10.1016/j.contraception.2008.01.016